Battelle Development Inventory Update 2016
2016 Update:
The previous blog post information is current and up to date.
Article Summary:
Devesa, J., Alonso, B., Casteleiro, N., Couto, P., Castañón, B., Zas, E., & Reimunde, P. (2011). Effects of recombinant growth hormone (GH) replacement and psychomotor and cognitive stimulation in the neurodevelopment of GH-deficient (GHD) children with cerebral palsy: a pilot study. Therapeutics and Clinical Risk Management, 7, 199–206. http://doi.org/10.2147/TCRM.S21403
The purpose of this pilot study is to assess the effect of growth hormone (GH) treatment combined with physical and cognitive therapy in children with Cerebral Palsy (CP) who are Growth Hormone deficient (GHD) on neurodevelopment. This study included 11 children 7 boys and 4 girls whose ages range from 3 to 7 years old. Each participant had received cognitive and physical therapy prior to the study. The children included in this study had known GHD and all other pituitary hormone deficiencies had been excluded by blood analysis. The Battelle Development Inventory Screening Test (BDIST) was used for all participants to assess neurodevelopment. The BDIST was administered 2 months prior to the GH treatment while participants received physical and cognitive therapy. The BDIST was administered again after the GH treatment. After 2 months of conservative treatment, the participants received physical and cognitive stimulation 45 minutes per day, 5 days per week combined with recombinant human GH given subcutaneously 30 µg/kg/day, 5days/week. Fasting blood samples were taken routinely throughout the 2 month combined treatment. The results of the study were determined by statistical analysis of the BDIST scores pre-treatment and post-treatment by the Wilcoxon signed-rank test. Participants improved significantly in personal and social skills, adaptive behavior, gross motor skills and total psychomotor abilities, receptive and total communication, cognitive skills and the total score with P<0.01. The improvements in fine motor skills and expressive communication were significant with P<0.02. Statistical analysis similar to the BDIST scores was performed on for the blood tests results throughout the study. The results showed plasma cholesterol and triglyceride values had decreased significantly, and no changes were observed in plasma glucose or TSH levels. The strength of this study is the use of the valid and reliable outcome measures and objective blood tests. The weakness of this study is the lack of control group and the small sample size. However, the pre-treatment group is similar to a control group. The overall conclusion of this pilot study is that GH treatment in conjunction with physical and cognitive therapy in children with CP who are GHD is effective in promoting appropriate neurodevelopment.
2 responses to “Battelle Development Inventory Update 2016”
Leave a Reply
You must be logged in to post a comment.
Good summary of the test and how it can be clinically applied. Seems to cover a very broad base of information which helps the test to be useful for many different aspects of a child’s plan of care. I compared your article with the one below and it was interesting to see how the BDI could be used in two very different areas. It seems many varying interventions and treatments can have an influence on the BDI which again contributes to it’s adaptability.
I wonder what the outcome would be with just PT?! Were the authors specific about what they did for PT, the frequency and duration?